Your browser is no longer supported. Please, upgrade your browser.
Settings
CMPI [NASD]
Checkmate Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own3.60% Shs Outstand21.56M Perf Week-8.88%
Market Cap226.62M Forward P/E- EPS next Y-2.91 Insider Trans3.50% Shs Float20.58M Perf Month-27.95%
Income-42.90M PEG- EPS next Q-0.67 Inst Own86.10% Short Float0.42% Perf Quarter-30.46%
Sales- P/S- EPS this Y-21.70% Inst Trans-0.02% Short Ratio1.96 Perf Half Y-14.13%
Book/sh5.81 P/B1.82 EPS next Y11.00% ROA-46.90% Target Price- Perf Year-
Cash/sh4.43 P/C2.39 EPS next 5Y45.10% ROE-481.10% 52W Range8.61 - 23.10 Perf YTD-27.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.51% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin- 52W Low0.58% ATR1.09
Employees25 Current Ratio13.00 Sales Q/Q- Oper. Margin- RSI (14)25.67 Volatility8.45% 8.59%
OptionableNo Debt/Eq0.00 EPS Q/Q-12.90% Profit Margin- Rel Volume1.64 Prev Close10.57
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume44.04K Price8.66
Recom1.70 SMA20-31.76% SMA50-36.81% SMA200-34.57% Volume55,693 Change-18.07%
Apr-12-21 08:36AM  
Apr-11-21 04:01PM  
Apr-09-21 02:16PM  
Mar-29-21 04:30PM  
Mar-10-21 04:30PM  
Jan-04-21 04:30PM  
Dec-20-20 02:14AM  
Dec-08-20 07:00AM  
Dec-01-20 06:30PM  
Nov-13-20 07:00AM  
Nov-09-20 09:00AM  
Nov-07-20 08:58AM  
Nov-03-20 07:00AM  
Oct-15-20 09:20AM  
Sep-23-20 07:00AM  
Sep-18-20 07:00AM  
Sep-09-20 01:00AM  
Aug-06-20 09:17PM  
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naive neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krieg Arthur MChief Scientific OfficerMar 26Buy12.153,48442,331746,711Mar 29 04:20 PM
Krieg Arthur MChief Scientific OfficerMar 25Buy12.3510,036123,945743,227Mar 29 04:20 PM
Chaudhary KleemChief Business OfficerFeb 26Option Exercise2.622,0005,2408,000Mar 01 04:15 PM
Krieg Arthur MChief Scientific OfficerJan 27Buy13.051,70122,198733,191Jan 28 04:05 PM
Krieg Arthur MChief Scientific OfficerJan 19Buy13.095006,545731,490Jan 21 05:17 PM
Chaudhary KleemChief Business OfficerJan 14Option Exercise2.622,0005,2406,000Jan 15 04:30 PM
Krieg Arthur MChief Scientific OfficerDec 29Buy14.164436,273730,990Dec 31 04:20 PM
Chaudhary KleemChief Business OfficerDec 22Option Exercise2.624,00010,4804,000Dec 23 04:15 PM
Krieg Arthur MChief Scientific OfficerDec 22Buy14.645,10374,708730,547Dec 23 04:13 PM
Krieg Arthur MChief Scientific OfficerDec 16Buy14.624,80570,249725,444Dec 17 05:21 PM
Krieg Arthur MChief Scientific OfficerDec 15Buy14.4942609720,639Dec 17 05:21 PM